|Bid||18.04 x 800|
|Ask||18.10 x 800|
|Day's Range||17.87 - 18.67|
|52 Week Range||11.75 - 27.68|
|Beta (5Y Monthly)||1.54|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Arrowhead Pharma posted positive clinical trials data on a promising drug to treat a rare genetic liver disease, and ARWR stock soared near a nine-moth high; shares of rival Dicerna also jumped.
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index was trading around the […]
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -304.76% and -46.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?